AdAlta (ASX:1AD) Pre-Tax Income : A$-5.04 Mil (TTM As of Dec. 2023)

View and export this data going back to 2016. Start your Free Trial

What is AdAlta Pre-Tax Income?

Pretax income is the income that a company earns before paying income taxes. AdAlta's pretax income for the six months ended in Dec. 2023 was A$-3.02 Mil. Its pretax income for the trailing twelve months (TTM) ended in Dec. 2023 was A$-5.04 Mil. AdAlta's pretax margin was %.

During the past 7 years, AdAlta's highest Pretax Margin was -613.46%. The lowest was -975.00%. And the median was -663.68%.

AdAlta Pre-Tax Income Historical Data

The historical data trend for AdAlta's Pre-Tax Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AdAlta Pre-Tax Income Chart

AdAlta Annual Data

Trend

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Pre-Tax Income

Get a 7-Day Free Trial

-5.92

-6.01

-5.63

-6.06

-4.85

AdAlta Semi-Annual Data
	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Pre-Tax Income	Get a 7-Day Free Trial										-3.66	-2.40	-2.82	-2.03	-3.02

Competitive Comparison of AdAlta's Pre-Tax Income

For the Biotechnology subindustry, AdAlta's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

AdAlta's Pre-Tax Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AdAlta's Pre-Tax Income distribution charts can be found below:

* The bar in red indicates where AdAlta's Pre-Tax Income falls into.

AdAlta Pre-Tax Income Calculation

This is the income that a company earns before paying income taxes.

AdAlta's Pretax Income for the fiscal year that ended in Jun. 2023 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-8.34	+	3.55	+	-0.124	+	0.063	+	8.8817841970013E-16
	=	-4.85

AdAlta's Pretax Income for the quarter that ended in Dec. 2023 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-4.085	+	1.11	+	-0.073	+	0.033	+	0
	=	-3.02

Pre-Tax Income for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$-5.04 Mil.

AdAlta (ASX:1AD) Pre-Tax Income Explanation

AdAlta's Pretax Margin for the quarter that ended in Dec. 2023 is calculated as

Pretax Margin	=	Pretax Income	/	Revenue
	=	-3.015	/	0
	=	%

During the past 7 years, AdAlta's highest Pretax Margin was -613.46%. The lowest was -975.00%. And the median was -663.68%.

AdAlta Pre-Tax Income Related Terms

Thank you for viewing the detailed overview of AdAlta's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.

AdAlta (ASX:1AD) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AdAlta Ltd (ASX:1AD) » Definitions » Pre-Tax Income

Comparable Companies

Traded in Other Exchanges

N/A

Address

2 Park Drive, Unit 15, Bundoora, VIC, AUS, 3083

Website

https://www.adalta.com.au

AdAlta Ltd is engaged in drug discovery and development company developing protein therapeutics, known as i-bodies, for treating a wide range of human diseases. The i-body candidate, AD-214, is being developed for the treatment of idiopathic pulmonary fibrosis and other fibrotic diseases, for which current therapies are sub-optimal. Its pipeline includes Fibrosis, and CAR-T cancer therapeutics.

AdAlta (ASX:1AD) Headlines

No Headlines